Option chain shows key data for Firstsun Capital's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Firstsun Capital.

Firstsun Capital (NASDAQ:FSUN) Stock, Option Chain

Firstsun Capital Bancorp is the financial holding company for Sunflower Bank, National Association. It provides a full range of deposit, lending, treasury management, wealth management and online banking products and services. The company operates in two segments - Banking operations and Mortgage operations, out of which the majority of the revenue is generated from the Banking operations segment.

Biotech

News

Penny Stocks

Guidance

Small Cap

General

BCAB

BDTX

ILMN

IMNM

NARI

NBSE

NTUS

PACB

SANA

SSKN

FSUN

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In

Earnings

IPOs

ABVC

ACAD

ACHL

ADGI

AGLE

AKRO

ALIM

ALKS

ALLO

ALZN

APRE

ARDS

ARNA

ATAI

AXSM

AYTU

BDSX

BIOL

BMEA

BNTX

BPTH

BXRX

CADL

CAPR

CELU

CLRB

CODX

CTMX

DMAC

DNAY

DRMA

DRNA

DVAX

ENSC

EPZM

EWTX

EYEG

FGEN

FLXN

FMTX

GILD

GRFS

GTBP

HARP

HBIO

HCWB

HOOK

HOTH

HRTX

IMRA

INAB

INCY

INVA

IPSC

IRTC

IRWD

ITRM

JAGX

JAZZ

KNSA

KPTI

KRON

LMNL

LUMO

LVTX

MBRX

MDNA

MNOV

MRNA

MYOV

NBIX

NKTR

ORTX

PASG

PBLA

PMCB

PRAX

PROG

RMTI

RPID

RVMD

SESN

SONN

SPRB

TARA

TFFP

TLGT

TNYA

TRIL

TRVN

TXMD

VECT

VYGR

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Aug. 12)

The Daily Biotech Pulse: Moderna&#39;s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz&#39;s Sleep Disorder Drug, Dermata IPO

Offerings

AMPE

APLS

ATXI

AVRO

BIIB

BOLT

CCCC

CNTA

ELOX

ENOB

IKNA

JANX

LMAT

MRVI

NAUT

NVAX

NVCR

OCDX

PDSB

PTGX

RAPT

RHHBY

SAGE

SWAV

TECH

VRTX

VSTM

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs June 14)

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda

Firstsun Capital Bancorp

Whales with a lot of money to spend have taken a noticeably bullish stance on Morgan Stanley.
Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 18 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $634,556 and 11, calls, for a total amount of $1,095,960.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $165.0 for Morgan Stanley, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Morgan Stanley's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Morgan Stanley's substantial trades, within a strike price spectrum from $85.0 to $165.0 over the preceding 30 days.
<h3>Morgan Stanley 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734984933_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.45</td>
<td>$14.3</td>
<td>$14.45</td>
<td>$125.00</td>
<td>$410.3K</td>
<td>236</td>
<td align="right">296</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$10.9</td>
<td>$10.7</td>
<td>$10.78</td>
<td>$120.00</td>
<td>$323.4K</td>
<td>70</td>
<td align="right">300</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$125.00</td>
<td>$216.0K</td>
<td>5.6K</td>
<td align="right">635</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$115.00</td>
<td>$82.5K</td>
<td>901</td>
<td align="right">250</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.3</td>
<td>$100.00</td>
<td>$79.9K</td>
<td>1.4K</td>
<td align="right">187</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
After a thorough review of the options trading surrounding Morgan Stanley, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Morgan Stanley's Current Market Status</h3>
<ul>
<li>With a volume of 1,743,969, the price of MS is up 0.61% at $124.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>Expert Opinions on Morgan Stanley</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; An analyst from HSBC has revised its rating downward to Hold, adjusting the price target to $131. 
&#x2A; An analyst from Keefe, Bruyette &amp; Woods has decided to maintain their Market Perform rating on Morgan Stanley, which currently sits at a price target of $138. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Morgan Stanley, targeting a price of $104. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Morgan Stanley with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Morgan Stanley's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DOW, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Dow.
This isn't normal.
The overall sentiment of these big-money traders is split between 11% bullish and 88%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $743,378, and there was 1 call, for a total amount of $283,023.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $50.0 for Dow over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Dow options trades today is 3337.2 with a total volume of 8,234.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Dow's big money trades within a strike price range of $45.0 to $50.0 over the last 30 days.
<h3>Dow Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734984928_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.45</td>
<td>$0.39</td>
<td>$0.41</td>
<td>$45.00</td>
<td>$283.0K</td>
<td>953</td>
<td>6.9K</td>
</tr>
<tr>
<td>DOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.95</td>
<td>$10.9</td>
<td>$10.95</td>
<td>$50.00</td>
<td>$257.3K</td>
<td>2.9K</td>
<td>470</td>
</tr>
<tr>
<td>DOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.9</td>
<td>$11.0</td>
<td>$50.00</td>
<td>$183.7K</td>
<td>2.9K</td>
<td>3</td>
</tr>
<tr>
<td>DOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.95</td>
<td>$10.85</td>
<td>$10.95</td>
<td>$50.00</td>
<td>$67.8K</td>
<td>2.9K</td>
<td>233</td>
</tr>
<tr>
<td>DOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.1</td>
<td>$8.0</td>
<td>$8.1</td>
<td>$45.00</td>
<td>$59.1K</td>
<td>1.9K</td>
<td>147</td>
</tr>
</tbody>
</table>

<h3>About Dow</h3>
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
After a thorough review of the options trading surrounding Dow, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Dow</h3>
<ul>
<li>With a volume of 4,189,600, the price of DOW is down -0.29% at $39.83. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 38 days.</li>
</ul>
<h3>What The Experts Say On Dow</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $48.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Dow, maintaining a target price of $44. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Dow, targeting a price of $47. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Dow, maintaining a target price of $41. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Dow, which currently sits at a price target of $55. 
&#x2A; In a positive move, an analyst from Evercore ISI Group has upgraded their rating to Outperform and adjusted the price target to $56. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Dow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on DOW Options

Investors with a lot of money to spend have taken a bearish stance on Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NET, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Cloudflare.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $123,510, and 5 are calls, for a total amount of $318,897.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $155.0 for Cloudflare during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cloudflare stands at 164.86, with a total volume reaching 615.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cloudflare, situated within the strike price corridor from $80.0 to $155.0, throughout the last 30 days.
<h3>Cloudflare Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734984923_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.2</td>
<td>$10.15</td>
<td>$10.15</td>
<td>$155.00</td>
<td>$153.7K</td>
<td align="right">13</td>
<td align="right">146</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$24.35</td>
<td>$24.1</td>
<td>$24.33</td>
<td>$90.00</td>
<td>$60.8K</td>
<td align="right">229</td>
<td align="right">30</td>
</tr>
<tr>
<td>NET</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.35</td>
<td>$4.3</td>
<td>$4.35</td>
<td>$112.00</td>
<td>$56.5K</td>
<td align="right">0</td>
<td align="right">131</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$114.00</td>
<td>$38.5K</td>
<td align="right">0</td>
<td align="right">131</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$42.65</td>
<td>$41.8</td>
<td>$41.8</td>
<td>$80.00</td>
<td>$37.6K</td>
<td align="right">159</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Cloudflare</h3>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Following our analysis of the options activities associated with Cloudflare, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Cloudflare</h3>
<ul>
<li>With a trading volume of 981,147, the price of NET is down by -1.05%, reaching $111.5.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Cloudflare</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $129.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley upgraded its action to Overweight with a price target of $130. 
&#x2A; An analyst from Jefferies has decided to maintain their Hold rating on Cloudflare, which currently sits at a price target of $125. 
&#x2A; An analyst from Mizuho has decided to maintain their Neutral rating on Cloudflare, which currently sits at a price target of $125. 
&#x2A; An analyst from Stifel has elevated its stance to Buy, setting a new price target at $136. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cloudflare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Decoding Cloudflare's Options Activity: What's the Big Picture?

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 5 years by 32.99% on an annualized basis producing an average annual return of 45.92%. Currently, Sprouts Farmers Market has a market capitalization of $12.93 billion. 
Buying $100 In SFM: If an investor had bought $100 of SFM stock 5 years ago, it would be worth $654.85 today based on a price of $129.31 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734984916_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Sprouts Farmers Market 5 Years Ago Would Be Worth Today

SLGL

Sol-Gel Technologies Shares Resume Trade Then Again Halted, This Time To The Downside, Stock Now Up 126.1%

Singapore-based Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) (the "Company" or "Davis Commodities"), has recently finalized a significant financial agreement, entering into a S$10,000,000 banking facility to fortify its operational capacities and propel strategic expansion efforts. This substantial facility stands as a part of foundation in supporting the Company's strategic expansion endeavors. With a well-structured financial framework in place, Davis Commodities is poised to leverage these allocated funds effectively, driving growth, and enhancing operational efficiency in the competitive landscape of commodity trading and financing.
To achieve greater profitability through our current resources and the bank facility requires a carefully crafted strategy customized to a company's unique operations, industry landscape, and risk appetite. Davis Commodities have set several strategic directions to stimulate growth and enhance financial outcomes.
Working Capital Optimization
One key avenue for optimizing the bank facility is through working capital management. By strategically allocating funds towards inventory purchases of high-margin, Davis Commodities can unlock significant value:
<ul>
<li>Negotiating bulk discounts with suppliers for large volume deals.</li>
<li>Enhancing cash flow by swiftly turning over inventories, thereby boosting revenue.</li>
</ul>
Expand Trade Credit
Extending trade credit to reliable customers and offering financing terms for larger orders can significantly boost sales volume and margins:
<ul>
<li>Providing short-term credit to customers.</li>
<li>Charging a small financing fee to enhance profitability.</li>
</ul>
Invest in Supply Chain Efficiencies
Investing in supply chain improvements is crucial for cost reduction and enhanced operational efficiency:
<ul>
<li>Allocating funds to streamline logistics operations and reduce delivery costs.</li>
<li>Establishing partnerships with shipping companies to secure lower rates and improve profit margins.</li>
</ul>
Hedging &amp; Arbitrage Opportunities
Another strategy involves capitalizing on price differentials in various markets through hedging and arbitrage:
<ul>
<li>Using funds to hedge against price fluctuations using futures contracts or options.</li>
<li>Exploiting price differentials by purchasing commodities in markets with lower prices and selling in regions with higher demand.</li>
</ul>
Leverage Financing for Higher ROI Projects
Identifying high-yield investment opportunities and utilizing debt responsibly to fund growth initiatives can drive substantial returns:
<ul>
<li>Investing in projects with good potential returns.</li>
<li>Ensuring that financing costs are covered by profit margins.</li>
</ul>
By effectively hedging positions and leveraging market disparities, Davis Commodities can secure profit margins and optimize returns on investments.
Secure Strategic Partnerships
By utilizing the bank facility as collateral and engaging in strategic partnerships, Davis Commodities can enhance its market position and product offerings through the following strategies:
<ul>
<li>Establishing joint ventures with suppliers or buyers.</li>
<li>Co-investing in commodity processing to improve margins and product value.</li>
</ul>
By implementing these strategic initiatives effectively, Davis Commodities can leverage its current resources and the bank facility to generate consistent profits, scale operations sustainably, and fortify its competitive edge in the dynamic commodity trading landscape.

Financing

Global

DTCK

Davis Commodities Secures S$10 Million Banking Facility To Fortify Its Operational Capacities And Propel Strategic Expansion Efforts

Sol-Gel Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 137.8%

WIIM

WISA

WiSA Technologies shares are trading higher after the company announced it received stockholder approval to purchase the Datavault intellectual property and information technology assets of privately held Data Vault Holdings.

Here's how we look at 2025 priorities:
<ul>
<li>First, we're laser focused on moving ahead with the potential acquisition anchored by the LOI. The next step is a definitive agreement to acquire that business.</li>
<li>We'll continue to market, distribute, install and sell both CLMBR and FORME to businesses and consumers worldwide continuing on the path we have demonstrated in Q3 and guided in Q4</li>
<li>We also expect to further strengthen our balance sheet to reinforce our ability to execute scaled M&amp;A more opportunistically.</li>
<li>We are already discussing additional, scaled acquisitions beyond the announced LOI, and will continue to identify and conduct due diligence on such opportunities.
<ul>
<li>We'll also continue to ramp up and improve our direct communications with all of our shareholders – everyone should sign up for direct emails from us; contact us; and visit not just our news page, but also <a href="https://interactivestrength.com/insights/">our new Insights page</a> – where we'll offer commentary on both TRNR and our markets.</li>
</ul>
</li>
</ul>

TRNR

Interactive Strength Shares 2025 Priorities, To Focus On Potential Acquisition, CLMBR And FORME Global Marketing Continuation, Balance Sheet Strengthening For Scaled M&A, Additional Acquisition Discussions Beyond LOI

In the current market session, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock price is at $254.02, after a 0.18% drop. However, over the past month, the company's stock spiked by 8.07%, and in the past year, by 31.58%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734984018_0.png" alt="Past Year Chart" />

<h3>Apple P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Apple has a better P/E ratio of 41.86 than the aggregate P/E ratio of 34.77 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that Apple Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734984018_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

AAPL

A Look Into Apple Inc's Price Over Earnings

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company&#8217;s Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea <a href="https://www.benzinga.com/general/health-care/24/12/42637278/eli-lillys-zepbound-receives-fda-approval-for-obesity-linked-sleep-apnea-drug">in adults with obesity.</a>
What To Know: After the market close on Friday, Eli Lilly announced FDA approval of Zepbound (tirzepatide) as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.
Obstructive sleep apnea is estimated to affect 50 million to 80 million people in the U.S., with an estimated 20 million suffering from moderate-to-severe forms. Clinical trials demonstrated the drug's efficacy, with nearly half of patients on the highest dose showing significant improvement in their apnea-hypopnea index, a primary diagnostic metric.
&#8220;Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences,&#8221; said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. &#8220;Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity.&#8221;
The approval is expected to impact insurance coverage for Zepbound, potentially expanding Medicare benefits for obesity-related treatments. In addition to improved obstructive sleep apnea symptoms, adults on Zepbound lost an average of 45 lbs (18%) of their body weight in Phase 3 trials.
The approval also positions Eli Lilly ahead of competitors like Novo Nordisk, whose Wegovy lacks approval for sleep apnea. The company's ongoing $3 billion investment in manufacturing capacity underscores its focus on meeting demand for its diabetes and obesity treatments.
Eli Lilly reported third-quarter revenue of $11.44 billion in October, reflecting a 20% year-over-year increase. Zepbound accounted for approximately $1.26 billion in total revenue during the quarter.
LLY Price Action: Eli Lilly shares were up 3.11% at $791.63 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh-1024x527.png" alt="" class="wp-image-704740" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh.png 1161w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42656283/pfizers-progress-on-c-diff-vaccine-and-pneumococcal-shot-wins-analyst-conviction">Pfizer&#8217;s Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction</a></li>
</ul>
Image Via Shutterstock.

Movers

Eli Lilly Stock Is Rising Monday: What's Going On?

CHEK

Check-Cap Shares Halted On Circuit Breaker To The Upside, Stock Now Up 386.4%

The semiconductor sector has had an electrifying run in recent years, but 2024 proved to be more selective. While some chipmakers soared to triple-digit gains, others <a href="https://www.benzinga.com/topic/chipmakers">struggled to stay afloat. </a>
As traders look forward to2025, a fresh question emerges: Should you chase the winners, pick the laggards, or focus on undervalued opportunities with high analyst backing?
The iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) delivered a 15.2% year-to-date gain as of Dec. 23, cooling off after a massive 65% surge in 2023. Within the group, performance varied wildly:
<ul>
<li>Top Performers: Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 180%, while Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) gained 109%.</li>
<li>Biggest Laggards: Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) sank 60%, Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) fell 36%, and ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) dropped 20%.</li>
</ul>
The key takeaway? The semiconductor market is far from homogenous, with companies diverging sharply based on their ability to capitalize on emerging trends like AI.
<h3 class="wp-block-heading">5 Chip Stocks Analysts Are Betting On for 2025</h3>
Rather than chasing laggards or jumping on already overheated names, traders might want to focus on undervalued semiconductor stocks that align with analysts' bullish forecasts. 
Here are five potential winners for 2025:
<h4 class="wp-block-heading">5. Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</h4>
<ul>
<li>Median Price Target (upside vs. current market price) : 32.02%</li>
<li>2024 YTD Performance: +3.29%</li>
<li>2023 Total Return: 67.97%</li>
<li>Market Cap: $136.21 billion</li>
<li>P/E Ratio (Next 12 Months): 17.7x</li>
</ul>
<h4 class="wp-block-heading">4. Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</h4>
<ul>
<li>Median Price Target (upside vs. current market price): 33.08%</li>
<li>2024 YTD Performance: -2.20%</li>
<li>2023 Total Return: 79.78%</li>
<li>Market Cap: $30.09 billion</li>
<li>P/E Ratio (Next 12 Months): 38.6x</li>
</ul>
<h4 class="wp-block-heading">3. Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</h4>
<ul>
<li>Median Price Target (upside vs. current market price): 43.12%</li>
<li>2024 YTD Performance: +4.80%</li>
<li>2023 Total Return: 71.93%</li>
<li>Market Cap: $99.64 billion</li>
<li>P/E Ratio (Next 12 Months): 11.4x</li>
</ul>
<h4 class="wp-block-heading">2. Advanced Micro Devices Inc. </h4>
<ul>
<li>Median Price Target (upside vs. current market price): 45.83%</li>
<li>2024 YTD Performance: -15.34%</li>
<li>2023 Total Return: 127.59%</li>
<li>Market Cap: $202.53 billion</li>
<li>P/E Ratio (Next 12 Months): 27.7x</li>
</ul>
<h4 class="wp-block-heading">1. Microchip Technology</h4>
<ul>
<li>Median Price Target (upside vs. current market price): 49.26%</li>
<li>2024 YTD Performance: -36.11%</li>
<li>2023 Total Return: 30.90%</li>
<li>Market Cap: $30.94 billion</li>
<li>P/E Ratio (Next 12 Months): 34.9x</li>
</ul>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42657620/amd-and-micron-top-analyst-picks-for-ai-and-next-gen-tech-growth">AMD and Micron Are Top Analyst Picks for AI and Next-Gen Tech Growth</a></li>
</ul>
Image: Shutterstock

Comments

Firstsun Capital

Firstsun Capital (FSUN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga